0 9 Selective selective JJ 10 21 DNA-binding dna-binding JJ 22 30 activity activity NN 31 33 of of IN 34 59 interleukin-10-stimulated interleukin-10-stimulated JJ 60 64 STAT stat NN 65 74 molecules molecule NNS 75 77 in in IN 78 83 human human JJ 84 93 monocytes monocyte NNS 93 94 . . . 96 98 It it PRP 99 102 has have VBZ 103 107 been be VBN 108 120 demonstrated demonstrate VBN 121 125 that that IN 126 142 interferon-gamma interferon-gamma NN 143 144 ( ( ( 144 153 IFN-gamma IFN-gamma NNP 153 154 ) ) ) 155 158 and and CC 159 173 interleukin-10 interleukin-10 NN 174 175 ( ( ( 175 180 IL-10 il-10 NN 180 181 ) ) ) 182 186 have have VBP 187 194 various various JJ 195 202 reverse reverse JJ 203 210 effects effect NNS 211 213 on on IN 214 225 macrophages macrophage NNS 225 226 ; ; : 227 234 however however RB 234 235 , , , 236 239 the the DT 240 249 molecular molecular JJ 250 259 mechanism mechanism NN 260 262 of of IN 263 267 this this DT 268 278 difference difference NN 279 282 has have VBZ 283 286 not not RB 287 291 been be VBN 292 297 fully fully RB 298 308 understood understand VBN 308 309 . . . 310 312 In in IN 313 317 this this DT 318 323 study study NN 323 324 , , , 325 327 we we PRP 328 336 analyzed analyze VBD 337 340 the the DT 341 348 binding binding NN 349 357 activity activity NN 358 360 of of IN 361 367 IL-10- IL-10- NNP 368 371 and and CC 372 391 IFN-gamma-activated ifn-gamma-activated JJ 392 396 STAT STAT NNP 397 406 molecules molecule NNS 407 409 to to TO 410 413 two two CD 414 419 kinds kind NNS 420 422 of of IN 423 432 GAS-motif gas-motif NN 433 442 sequences sequence NNS 442 443 . . . 444 459 IL-10-activated il-10-activated JJ 460 465 STAT1 STAT1 NNP 466 471 could could MD 472 476 bind bind VB 477 479 to to TO 480 483 the the DT 484 493 GAS-motif gas-motif JJ 494 502 sequence sequence NN 503 505 in in IN 506 509 the the DT 510 518 promoter promoter NN 519 525 region region NN 526 528 of of IN 529 532 the the DT 533 540 Fcgamma Fcgamma NNP 541 549 receptor receptor NN 549 550 , , , 551 554 but but CC 555 558 not not RB 559 561 to to TO 562 566 that that DT 567 569 in in IN 570 573 the the DT 574 582 promoter promoter NN 583 589 region region NN 590 592 of of IN 593 596 the the DT 597 602 COX-2 cox-2 NN 603 607 gene gene NN 607 608 , , , 609 616 whereas whereas IN 617 636 IFN-gamma-activated ifn-gamma-activated JJ 637 642 STAT1 STAT1 NNP 643 646 and and CC 647 652 STAT5 STAT5 NNP 653 658 could could MD 659 663 bind bind VB 664 666 to to TO 667 671 both both DT 672 681 sequences sequence NNS 681 682 . . . 683 688 IL-10 IL-10 NNP 689 698 inhibited inhibit VBD 699 716 IFN-gamma-induced ifn-gamma-induced JJ 717 721 STAT STAT NNP 722 732 activation activation NN 733 740 without without IN 741 746 newly newly RB 747 758 synthesized synthesize VBN 759 766 protein protein NN 766 767 . . . 768 770 We we PRP 771 778 further further RB 779 791 demonstrated demonstrate VBD 792 796 that that IN 797 804 aspirin aspirin NN 804 805 , , , 806 809 but but CC 810 813 not not RB 814 827 dexamethasone dexamethasone NN 827 828 , , , 829 839 suppressed suppress VBD 840 857 IFN-gamma-induced ifn-gamma-induced JJ 858 862 STAT STAT NNP 863 873 activation activation NN 873 874 . . . 875 880 Taken take VBN 881 889 together together RB 889 890 , , , 891 896 these these DT 897 904 results result NNS 905 912 suggest suggest VBP 913 917 that that IN 918 933 IL-10-activated il-10-activated JJ 934 939 STAT1 stat1 NN 940 943 has have VBZ 944 945 a a DT 946 957 specificity specificity NN 958 960 in in IN 961 968 binding bind VBG 969 971 to to TO 972 975 the the DT 976 985 GAS-motif gas-motif NN 986 995 sequences sequence NNS 995 996 , , , 997 1004 whereas whereas IN 1005 1024 IFN-gamma-activated ifn-gamma-activated JJ 1025 1030 STAT1 STAT1 NNP 1031 1034 and and CC 1035 1040 STAT5 STAT5 NNP 1041 1045 have have VBP 1046 1047 a a DT 1048 1055 broader broad JJR 1056 1064 spectrum spectrum NN 1065 1067 in in IN 1068 1075 binding bind VBG 1076 1078 to to TO 1079 1082 the the DT 1083 1092 GAS-motif gas-motif NN 1093 1102 sequences sequence NNS 1102 1103 . . . 1104 1108 This this DT 1109 1112 may may MD 1113 1120 explain explain VB 1121 1124 the the DT 1125 1135 difference difference NN 1136 1143 between between IN 1144 1149 IL-10 IL-10 NNP 1150 1153 and and CC 1154 1163 IFN-gamma IFN-gamma NNP 1164 1166 in in IN 1167 1177 biological biological JJ 1178 1186 activity activity NN 1186 1187 , , , 1188 1191 and and CC 1192 1195 the the DT 1196 1206 inhibitory inhibitory JJ 1207 1213 effect effect NN 1214 1216 of of IN 1217 1222 IL-10 IL-10 NNP 1223 1225 on on IN 1226 1235 IFN-gamma IFN-gamma NNP 1236 1246 activities activity NNS 1246 1247 . . .